The estimated Net Worth of Steven G. Brodie is at least $1.28 Milion dollars as of 22 October 2018. Dr Brodie owns over 13,334 units of Neogenomics stock worth over $749,493 and over the last 10 years he sold NEO stock worth over $528,900.
Dr has made over 7 trades of the Neogenomics stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 13,334 units of NEO stock worth $46,002 on 22 October 2018.
The largest trade he's ever made was selling 50,000 units of Neogenomics stock on 13 March 2017 worth over $396,500. On average, Dr trades about 15,119 units every 74 days since 2015. As of 22 October 2018 he still owns at least 45,953 units of Neogenomics stock.
You can see the complete history of Dr Brodie stock trades at the bottom of the page.
Dr. Steven G. Brodie FACMG, Ph.D. is the Sr. VP of Laboratory Operations at Neogenomics.
Dr D is 60, he's been the Sr. VP of Laboratory Operations of Neogenomics since . There are 6 older and 19 younger executives at Neogenomics. The oldest executive at Neogenomics Inc. is Raymond Hipp, 77, who is the Independent Director.
Steven's mailing address filed with the SEC is 12701 COMMONWEALTH DRIVE SUITE 9, , FORT MYERS, FL, US 33913.
Over the last 12 years, insiders at Neogenomics have traded over $310,374,253 worth of Neogenomics stock and bought 167,456 units worth $1,699,153 . The most active insiders traders include Electric Coge Medical Syste..., Oort Douglas M Van oraz Steven C Jones. On average, Neogenomics executives and independent directors trade stock every 23 days with the average trade being worth of $2,654,175. The most recent stock trade was executed by Alicia C Olivo on 15 August 2024, trading 1,040 units of NEO stock currently worth $16,692.
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig
Neogenomics executives and other stock owners filed with the SEC include: